Athira Pharma, Inc. — Director's Dealing 2021

Feb 22, 2021

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Athira Pharma, Inc. (ATHA)
CIK: 0001620463
Period of Report: 2021-02-18

Reporting Person: MOEBIUS HANS (Chief Medical Officer)

Derivative Transactions

Date	Security	Exercise Price	Code	Shares	A/D	Expiration	Underlying	Ownership
2021-02-18	Stock Option (Right to Buy)	$21.15	A	72000	Acquired	2031-02-17	Common Stock (72000)	Direct

Footnotes

F1: One-fourth of the shares subject to the option will vest on January 8, 2022, and one-fourth of the shares subject to the option will vest on each year thereafter.